Previous 10 |
home / stock / kttaw / kttaw news
MIAMI BEACH, Fla., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological dis...
-- Pasithea Clinics to offer ketamine infusion therapy for the treatment of mental health disorders -- -- First mobile clinics launch in New York City, Los Angeles, San Diego, and San Francisco, with expansion to additional U.S. cities in coming months -- -- Treatments conducted b...
MIAMI BEACH, Fla., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (Pasithea or the Company), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced that its...
MIAMI BEACH, Fla., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders...
MIAMI BEACH, Fla., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological dis...
-- Pasithea Clinics partners with ZEN Healthcare – a network of health clinics in Central London – to offer ketamine infusion therapy for the treatment of mental health disorders -- -- Ketamine in sub-anesthetic doses has shown to be highly effective at treating some psy...
MIAMI BEACH, Fla., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders...
MIAMI BEACH, Fla., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorder...
MIAMI BEACH, Fla., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorder...
News, Short Squeeze, Breakout and More Instantly...
Pasithea Therapeutics Corp. Warrant Company Name:
KTTAW Stock Symbol:
NASDAQ Market:
Pasithea Therapeutics Corp. Warrant Website:
MIAMI, June 13, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis typ...
-- PAS-004 inhibition of in vitro NRAS cell lines does not plateau in contrast to approved MEK inhibitors -- -- PAS-004 inhibition of in vitro NRAS cell lines is greater than selumetinib and binimetinib and similar to trametinib -- -- PAS-004 shows superior activity versus selumetinib and...
SOUTH SAN FRANCISCO, Calif. and MIAMI, April 29, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the tr...